

Bibliographic Information

Remedies for endothelin-induced diseases. Yuyama, Hironori; Fujimori, Akira; Sanagi, Masanao; Harada, Hironori; Koakutsu, Akiko; Mori, Mikiko; Yamamoto, Nobuyuki. (Yamanouchi Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. (2001), 27 pp. CODEN: PIXXD2 WO 2001060370 A1 20010823 Designated States W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM. Designated States RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, ML, MR, NE, SN, TD, TG. Patent written in Japanese. Application: WO 2000-JP7573 20001027. Priority: JP 2000-37313 20000216; JP 2000-37314 20000216. CAN 135:200444 AN 2001:617825 CAPLUS

Patent Family Information

| Patent No. | Kind | Date | Application No. | Date |
|---|------|----------|-----------------|----------|
| WO 2001060370 | A1 | 20010823 | WO 2000-JP7573 | 20001027 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2000079614 | A5 | 20010827 | AU 2000-79614 | 20001027 |
| JP 2001302514 | A2 | 20011031 | JP 2000-328374 | 20001027 |
| CA 2395711 | AA | 20020718 | CA 2000-2395711 | 20001027 |
| EP 1256344 | A1 | 20021113 | EP 2000-970160 | 20001027 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| BR 2000017120 | A | 20030114 | BR 2000-17120 | 20001027 |
| US 6774131 | B1 | 20040810 | US 2002-181489 | 20020719 |

Priority Application

| | | |
|----------------|---|----------|
| JP 2000-37313 | A | 20000216 |
| JP 2000-37314 | A | 20000216 |
| WO 2000-JP7573 | W | 20001027 |

Abstract

Disclosed are drug compns. for treatment of prostatic cancer, contg. as the active ingredient N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-phenyl-ethenesulfonamide (I) or pharmaceutically acceptable salts thereof. The inhibitory effect of compd. I on endothelin-1 (ET-1)-induced cell proliferation in hormone-independent human prostate cancer cell line (PPC-1).